EyePoint, Inc (EYPT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $35.00M
Last updated: Nov 17, 2026 at 4:28 PM ET
EyePoint, Inc (EYPT) Statistics
EyePoint (EYPT) has a market cap of $35.00M. It kept -13286.38% of revenue as net income over the last 12 months. It holds $83.21M more cash than debt, 237.73% of its market cap.
Total Valuation
| Market Cap | $35.00M |
|---|---|
| Latest price (Nov 17, 2026) | $0.30 |
Key Dates
The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 10.2x and 0.2x. Its year-end P/S ranged from 1.3x to 40.8x from 2016 to 2025.
| P/S Ratio | 10.2x |
|---|---|
| Forward P/S | 15.8x |
| P/B Ratio | 0.2x |
Price Statistics
The stock is down 97.44% over 52 weeks and trades 86.11% below its 50-day average.
| Beta (1Y) | 1.18 |
|---|---|
| 52-Week Change | -97.44% |
| 1-Month Change | -32.75% |
| 3-Month Change | -95.30% |
| 6-Month Change | -97.50% |
| 5-Year Change | -96.96% |
| 10-Year Change | -98.32% |
| Total Return (1Y) | -97.44% |
| Total Return (3Y CAGR) | -64.56% |
| Total Return (5Y CAGR) | -55.22% |
| Max Drawdown (1Y) | -98.43% |
| Max Drawdown (3Y) | -99.00% |
| Sharpe Ratio (1Y) | -1.66 |
| Correlation with SPY (1Y) | 0.07 |
| 50-Day Average | $2.16 |
| 200-Day Average | $10.10 |
| 52-Week Range | $0.28 to $19.11 |
| RSI (14 Days) | 18.1 |
| Average Volume (20 Days) | 7.82M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.30x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.30x |
|---|---|
| Quick Ratio | 3.25x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -315.67% over the last 12 months, against a 5-year average of -55.81%.
| Return on Equity (ROE) | -315.67% |
|---|---|
| Return on Assets (ROA) | -206.17% |
| Return on Capital Employed (ROCE) | -268.24% |
| ROE (5Y Average) | -55.81% |
| ROA (5Y Average) | -38.76% |
| ROIC (5Y Average) | -43.27% |
| Asset Turnover | 0.01x |
| Inventory Turnover | 1.16x |
| Receivables Turnover | 14.94x |
| Cash Conversion Cycle | -2535 days |
Scores
EYPT has an Altman Z-Score of -17.50, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -17.50 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $2.58M over the last 12 months is down 93.91% from the 12 months before.
| Revenue | $2.58M |
|---|---|
| Revenue Growth (YoY) | -93.91% |
| Gross Profit | $512.00K |
| Operating Income | -$351.83M |
| Pretax Income | -$342.39M |
| Net Income | -$342.52M |
| EBITDA | -$341.45M |
| EBIT | -$342.35M |
| Reported EPS (TTM) | -$3.96 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 65.31% of the $166.14M in total assets.
| Cash and Equivalents | $83.21M |
|---|---|
| Total Debt | $0 |
| Net Cash | $83.21M |
| Net Cash Per Share | $0.93 |
| Working Capital | $88.48M |
| Shareholder Equity | $108.51M |
| Book Value Per Share | $1.22 |
| Total Assets | $166.14M |
| Total Liabilities | $57.63M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $4.39M of capital spending, operating cash flow left -$299.15M of free cash flow.
| Operating Cash Flow | -$294.76M |
|---|---|
| Capital Expenditures | $4.39M |
| Free Cash Flow | -$299.15M |
| FCF Per Share | -$3.57 |
| Depreciation and Amortization | $4.73M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -13647.32%.
| Gross Margin | 19.86% |
|---|---|
| Operating Margin | -13647.32% |
| Pretax Margin | -13281.11% |
| Net Margin | -13286.38% |
| EBITDA Margin | -13244.69% |
| EBIT Margin | -13279.83% |
| FCF Margin | -11603.92% |
| Gross Margin (5Y Average) | 90.23% |
Growth
Revenue fell 8.83% a year over 3 years.
| Revenue Growth (3Y CAGR) | -8.83% |
|---|---|
| Revenue Growth (5Y CAGR) | -14.55% |
| Book Value Per Share Growth (2Y CAGR) | -23.60% |
| Tangible Book Per Share Growth (2Y CAGR) | -23.60% |
Dividends and Yields
EYPT does not pay a dividend. Its free cash flow yield is -1132.81%.
| FCF Yield | -1132.81% |
|---|---|
| Buyback Yield | -798.54% |
| Shareholder Yield | -798.54% |
Stock Splits
The last split was a 1-for-10 reverse split on Dec 9, 2020.
| Last Split Date | Dec 9, 2020 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 5 similar companies, EYPT has the 3rd highest P/S.
P/S RatioPeer median 9.7x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -32.90%
| P/S Ratio | 10.2x vs 9.7x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -93.91% vs -32.90% median |
Analyst Forecast
Consensus estimates put revenue growth at -58.64% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -58.64% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EYPT
What is EYPT's market cap?
EyePoint has a market cap of $35.00M.
How many shares of EYPT are outstanding?
EyePoint has 89.25M shares outstanding. The count is up 27.19% from a year earlier.
Does EYPT pay a dividend?
No. EyePoint does not pay a dividend.
How much debt does EYPT have?
EyePoint has $0 of total debt and $83.21M of cash and equivalents, a net cash position of $83.21M.
EYPT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors